Verification of Predictive Biomarkers for Pancreatic Cancer Treatment Using Multicenter Liquid Biopsy
Verification of Predictive Biomarkers for Pancreatic Cancer Treatment Using Multicenter Liquid Biopsy
This study is for verification of predictive biomarkers for pancreatic cancer treatment using
 multi-center liquid biopsy.
Clinical applicability of KRAS mutations using circulating-tumor DNA in pancreatic cancer
 patients.

 -  Quantification and monitoring of KRAS mutations Using droplet digital PCR in ctDNA
 extracted from collected patient samples.

 -  Correlation analysis of KRAS mutation results with clinical data.

 Discovery of biomarkers for predicting pancreatic cancer prognosis through ctDNA panel.

 -  Gene panel composition for pancreatic cancer therapeutic target determination and
 monitoring.

 -  A panel was performed using gDNA and ctDNA of tumor tissue collected from pancreatic
 cancer patients.

 -  Comparative analysis of panel results and quantitative KRAS mutations and evaluation of
 clinical applicability.
Inclusion Criteria:

 -  Patients with pathologically confirmed pancreatic adenocarcinoma.

 Exclusion Criteria:

 -  Patients disagree with the study.